硼替佐米
多发性骨髓瘤
体内
医学
药理学
中止
蛋白酶体抑制剂
骨髓
Carfilzomib公司
癌症研究
内科学
生物
生物技术
作者
Hua Wang,Luo Xiao,Jianguo Tao,Venkat Srinivasan,Brendan F. Boyce,Frank H. Ebetino,Babatunde O. Oyajobi,Robert K. Boeckman,Lianping Xing
出处
期刊:Pharmaceutics
[MDPI AG]
日期:2018-09-10
卷期号:10 (3): 154-154
被引量:28
标识
DOI:10.3390/pharmaceutics10030154
摘要
Multiple myeloma (MM) is the most common cancer affecting the bone and bone marrow and remains incurable for most patients; novel therapies are therefore needed. Bortezomib (Btz) is an FDA-approved drug for the treatment of patients with MM. However, its severe side effects require a dose reduction or the potential discontinuation of treatment. To overcome this limitation, we conjugated Btz to a bisphosphonate (BP) residue lacking anti-osteoclastic activity using a novel chemical linker and generated a new bone-targeted Btz-based (BP-Btz) proteasome inhibitor. We demonstrated that BP-Btz, but not Btz, bound to bone slices and inhibited the growth of MM cells in vitro. In a mouse model of MM, BP-Btz more effectively reduced tumor burden and bone loss with less systemic side effects than Btz. Thus, BP-Btz may represent a novel therapeutic approach to treat patients with MM.
科研通智能强力驱动
Strongly Powered by AbleSci AI